Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Invitation to Alligator Bioscience's Interim Report Call on 22 October 2026

accessnewswire.com
HLX The article is an invitation to an interim report call and does not provide any performance data or forward-looking statements that would indicate a specific sentiment. It focuses on the logistics of the report release and call.

Invitation to Alligator Bioscience's Interim Report Call on 22 October 2026 LUND, SE / ACCESS Newswire / October 15, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody programme HLX22, will publish its interim report for July - September 2026 on Thursday, 22 October 2026, at 8:00 a.m. CEST.

On the same day, Alligator will host a webinar and conference call for investors, analysts and media at 2:00 p.m. CEST / 8:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report. The presentation will be followed by a Q&A session.

The call will be held in English. Attendees are required to register in advance via this link and are welcome to submit questions in advance to [email protected].

The full report will be available upon publication on Alligator's website.

For further information, please contact:

Søren Bregenholt, CEO

E-mail: [email protected]

Phone: +46 (0) 46 540 82 00

Johan Giléus, CFO

E-mail: [email protected]

Phone: +46 (0) 46 540 82 00

The information was submitted for publication, through the agency of the contact persons set out above, at 2:00 p.m. CEST on 15 October 2026.

About Alligator Bioscience

Alligator is a biotechnology company that has historically focused on tumor-directed immuno-oncology. Following a strategic refocus, Alligator is prioritizing the value of its economic interest in HLX22, an anti-HER2 monoclonal antibody being developed by Shanghai Henlius Biotech Inc., from which Alligator is entitled to a share of revenues without incurring development costs. Alligator has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset in the near term.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Invitation to Alligator Bioscience's interim report call on 22 October 2026

SOURCE: Alligator Bioscience